Joincare Pharmaceutical Group Industry Co. Ltd. provided earnings guidance for the full year of 2017. For the year, the company predicts that the net profit belonging to shareholders will increase by between RMB 1,636 million and RMB 1,733 million with an increase of between 362.51% and 383.92% compared with the same period of the year before (based on the disclosed statistics according to relevant regulations). The net profit belonging to shareholders after excluding extraordinary profit and loss will increase by between RMB 151 million and RMB 197 million with an increase of between 47.80% and 62.59% compared with the same period of the year before (based on the disclosed statistics according to relevant regulations).